IPO Calendar
Lead Manager
- J P Morgan Chase (482)
- Goldman Sachs (458)
- Morgan Stanley (413)
- Bank of America Merrill Lynch (354)
- Citigroup (222)
- Jefferies (211)
- Credit Suisse (180)
- Barclays (150)
- Cowen and Company (145)
- Deutsche Bank (81)
- Piper Jaffray (70)
- Leerink Partners (69)
- Stifel (65)
- UBS Investment Bank (52)
- Evercore (51)
- RBC Capital (50)
- BMO Capital (49)
- Wells Fargo (45)
- William Blair (37)
- Raymond James (36)
More +
IPO - Pricing (51)
Evercore
UnderWriters* | |||||||||||
Date | Company Name | Sector | Price ($) |
Size (M) |
1 | 2 | 3 | Rank | Turnover | Gain | |
---|---|---|---|---|---|---|---|---|---|---|---|
Nov 7 | Triumph Bancorp | Finance | 12 | 6 | EVCR | SNDL | WLFG | 26.2% | 6.3% | ||
Oct 2 | NovoCure Limite | Health-Care | 22 | 7 | DB | EVCR | JPM | 42.8% | -16.9% | ||
Jun 22 | electroCore Inc | Health-Care | 15 | 5 | EVCR | JMPS | PPRJ | 35.2% | 32.3% | ||
Sep 15 | RayzeBio, Inc. | Health Care | 18 | 17 | JPM | EVCR | TS | 23.1% | 33.3% | ||
Feb 15 | Stealth BioTher | NA | 12 | 6 | JEFF | EVCR | BMO | 17.5% | -0.8% | ||
Jun 20 | Atreca Inc. | NA | 17 | 7 | COWN | EVCR | Stifel | 34.1% | 6.2% | ||
Jun 20 | Akero Therapeut | NA | 16 | 5 | JPM | JEFF | EVCR | 51.9% | 14.5% | ||
Jul 18 | Mirum Pharmaceu | Health-Care | 15 | 5 | CITI | EVCR | GGNH | 29.5% | -11.9% | ||
Oct 17 | Innate Pharma S | Health-Care | 5.5 | 12 | CITI | EVCR | 6.6% | 10% | |||
Oct 25 | Phathom Pharmac | Health-Care | 19 | 9 | GS | JEFF | EVCR | 9% | 29.5% | ||
Oct 25 | Cabaletta Bio I | Health-Care | 11 | 6 | MS | COWN | EVCR | 14.3% | -9.1% | ||
Oct 25 | Aesthetic Medic | Health-Care | 12 | 2 | MS | COWN | EVCR | 31% | -16.4% | ||
Nov 7 | Centogene B.V. | Health-Care | 14 | 4 | LRNK | EVCR | 23.2% | -10.8% | |||
May 21 | SelectQuote Inc | Finance | 20 | 28 | CS | MS | EVCR | 71.4% | 35% | ||
Jul 10 | Nkarta Inc. | Health-Care | 18 | 14 | COWN | EVCR | Stifel | 9.4% | 166.1% | ||
Jul 16 | Trean Insurance | Finance | 15 | 10 | JPM | EVCR | WB | 71.2% | 3.4% | ||
Aug 7 | Freeline Therap | Health-Care | 18 | 8 | JPM | MS | EVCR | 31.5% | 0% | ||
Aug 19 | Inhibrx Inc. | Health-Care | 17 | 7 | JEFF | EVCR | CS | 6.4% | 21.5% | ||
Aug 18 | COMPASS Pathway | Health-Care | 17 | 7 | COWN | EVCR | 40% | 70.6% | |||
Oct 2 | Oncorus Inc. | Health-Care | 15 | 5 | JEFF | EVCR | PPRJ | 12.6% | 6.7% | ||
Oct 2 | C4 Therapeutics | Health-Care | 19 | 9 | JEFF | EVCR | BMO | 20.3% | 34.2% | ||
Oct 8 | fuboTV Inc. (fo | Consumer-Services | 10 | 18 | EVCR | 58.8% | 2.6% | ||||
Oct 14 | Codiak BioScien | Health-Care | 15 | 5 | GS | EVCR | WB | 41.3% | -19.2% | ||
Oct 16 | PRAXIS PRECISIO | Health-Care | 19 | 10 | COWN | EVCR | WBSH | 43.2% | 46.3% | ||
Oct 30 | SQZ Biotechnolo | Health-Care | 16 | 4 | BAML | EVCR | Stifel | 19.2% | -17.2% | ||
Oct 30 | Atea Pharmaceut | Health-Care | 24 | 12 | JPM | MS | EVCR | 28.6% | 26.4% | ||
Feb 10 | Mineralys Thera | Health Care | 16 | 12 | BAML | EVCR | Stifel | 22.6% | 15.3% | ||
Dec 11 | 4D Molecular Th | Health-Care | 23 | 8 | GS | BAML | EVCR | 43.5% | 76.1% | ||
Jan 8 | Cullinan Oncolo | Health-Care | 29.9 | 21 | MS | LRNK | EVCR | 19.3% | 0% | ||
Feb 5 | Vor Biopharma I | Health-Care | 18 | 9 | GS | EVCR | BRCL | 33.9% | 108.3% | ||
Mar 19 | Finch Therapeut | Health-Care | 17 | 7 | BAML | JEFF | EVCR | 28.1% | 25.4% | ||
Apr 30 | Werewolf Therap | Health-Care | 16 | 7 | JEFF | SVB | EVCR | 45.8% | 0.6% | ||
May 7 | Talaris Therape | Health-Care | 17 | 8 | MS | SVB | EVCR | 33.4% | -4.4% | ||
May 14 | Vera Therapeuti | Health-Care | 11 | 4 | JEFF | COWN | EVCR | 14.8% | 4.5% | ||
Jun 11 | Janux Therapeut | Health-Care | 17 | 11 | BAML | COWN | EVCR | 20.9% | 47.9% | ||
Jun 30 | Integral Ad Sci | Technology | 18 | 15 | MS | JEFF | EVCR | 56.1% | 14.3% | ||
Jun 30 | Aerovate Therap | Health-Care | 14 | 8 | JEFF | COWN | EVCR | 13% | 63.1% | ||
Jul 29 | Rallybio Corp. | Health-Care | 13 | 6 | JEFF | COWN | EVCR | 10.8% | 8.5% | ||
Jul 29 | Icosavax Inc. | Health-Care | 15 | 12 | JEFF | COWN | EVCR | 25.9% | 133.1% | ||
Aug 10 | Eliem Therapeut | Health-Care | 12.5 | 6 | SVB | EVCR | Stifel | 23.8% | 27.2% | ||
Sep 15 | DICE Therapeuti | Health-Care | 17 | 12 | BAML | SVB | EVCR | 12.2% | 117% | ||
Oct 8 | IsoPlexis Corp. | Health-Care | 15 | 8 | MS | COWN | EVCR | 47% | -23.2% | ||
Oct 15 | MiNK Therapeuti | Health-Care | 12 | 3 | EVCR | WB | 21.5% | 0% | |||
Oct 20 | Ventyx Bioscien | Health-Care | 16 | 9 | JEFF | EVCR | PPRJ | 17.9% | 31.4% | ||
Oct 29 | Aura Bioscience | Health-Care | 14 | 5 | COWN | SVB | EVCR | 29.1% | 5.7% | ||
Nov 11 | Vaxxinity Inc. | Health-Care | 13 | 6 | BAML | JEFF | EVCR | 62.6% | 27.3% | ||
Jan 7 | CinCor Pharma I | Health-Care | 16 | 12 | MS | JEFF | EVCR | 23.2% | 0% | ||
Jan 7 | Amylyx Pharmace | Health-Care | 19 | 10 | GS | LRNK | EVCR | 21.6% | -4.9% | ||
Mar 25 | AN2 Therapeutic | Health-Care | 15 | 4 | COWN | SVB | EVCR | 30.2% | 2.7% | ||
Jun 6 | Life360, Inc. | Technology | 27 | 5 | GS | EVCR | UBS | 18% | 0% | ||
Sep 26 | BKV Corporation | Energy | 18 | 15 | CITI | BRCL | EVCR | 40.4% | 0% |
*
Lead manager or one of top three managers in an underwriting team.